Europe Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavir

Europe Vaccines Market By Technology Type (Inactivated Vaccines, Toxoid Vaccines, Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Others) , By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP) , Polio, Hepatitis, Other Indications) By End User (Pediatric, Adults, Travelers) : Opportunity Analysis and Industry Forecast, 2024-2033

The Europe vaccines market was valued at $12.1 billion in 2023, and is projected to reach $22.3 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.

Vaccine is a suspension of killed, weakened, or fragmented toxins, microorganisms, or other biological preparation such as those consisting of lymphocytes, antibodies, or messenger RNA (mRNA), that is administered to prevent diseases. The goal of vaccination is to prepare the body’s immune defenses to respond effectively if exposed to the pathogen in the future, thereby preventing illness or reducing its severity.

The growth of the Europe vaccines market is majorly driven by alarming rise in burden of diseases such as measles, influenza, meningitis, and human papillomavirus. A study by Statista revealed that in 2023, approximately 4,000 measles cases were reported in the European Economic Area (EEA), with Romania accounting for nearly 3,400 cases, indicating a significant concentration of outbreaks in specific regions. Furthermore, strong governmental support through routine immunization programs, subsidies, and awareness campaigns significantly contributes toward the growth of the market. For instance, the European Centre for Disease Prevention and Control (ECDC) emphasizes vaccination programs to combat seasonal outbreaks. Initiatives like the European Immunization Week further aim to boost public confidence in vaccines and promote their adoption. In addition, increase in awareness among the population about the importance of vaccination in preventing life-threatening diseases encourages higher immunization rates. This is further supported by educational efforts from healthcare organizations. According to Statista, approximately 92.4% of children in the European Economic Area (EEA) received their first dose of the measles vaccination, whereas 89.7% received their second dose. The World Health Organization recommends a 95% vaccination rate to halt the spread of preventable diseases. Moreover, surge in geriatric population acts as the key driving force of the market. This is attributed to the fact that Europe’s aging demographic has led to an increased demand for vaccines targeting age-related infections, such as pneumococcal and herpes zoster vaccines, to reduce healthcare costs and morbidity in older adults. Despite strong public health initiatives, vaccine hesitancy remains a significant barrier, influenced by misinformation, cultural beliefs, and distrust in pharmaceutical companies. The World Health Organization lists vaccine hesitancy as one of the top ten global health threats. Moreover, high cost associated with research, development, and manufacturing of vaccines significantly hampers the market growth. On the contrary, innovations such as mRNA-based vaccines, recombinant protein vaccines, and needle-free delivery methods have enhanced the efficiency, safety, and accessibility of vaccines, which are expected to offer remunerative opportunities for the expansion of the market during the forecast period.

The Europe vaccines market size is segmented into technology type, indication, end user, and country. On the basis of technology type, the market is categorized into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, and rubella; diphtheria, pertussis, and tetanus (DTP); polio; hepatitis; and other indications. Depending on end user, it is segregated into pediatric, adults, and travelers. Country wise, the Europe vaccines industry is analyzed across Germany, France, UK, Italy, Spain, and rest of Europe.

Competition Analysis

The major players operating in the Europe vaccines market include Pfizer, Bavarian Nordic A/S, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, Sanofi, Prokarium, Merck & Co., Inc., and GSK Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the market.

Key Market Segments

By Technology Type

Inactivated Vaccines
Toxoid Vaccines
Recombinant and Conjugate Vaccines
Live Attenuated Vaccines
Others

By Indication

Pneumococcal Disease
Influenza
Human Papilloma Virus
Meningococcal Disease
Rotavirus
Varicella
Measles, Mumps, and Rubella
Diphtheria, Pertussis, and Tetanus (DTP)
Polio
Hepatitis
Other Indications

By End User

Pediatric
Adults
Travelers

By Country

Germany
France
UK
Italy
Spain
Rest Of Europe

Key Market Players

Pfizer
Bavarian Nordic A/S
Valneva SE
Viatris Inc.
AstraZeneca
Emergex Vaccines
Sanofi
Prokarium
Merck & Co., Inc.
GSK plc.